Unicycive Therapeutics, Inc. (UNCY) |
|
0.56 -0.043 (-7.05%)
|
01-27 16:00 |
|
Open: |
0.59 |
Pre. Close: |
0.6025 |
|
High:
|
0.6124 |
Low:
|
0.5421 |
|
Volume:
|
67,968 |
Market Cap:
|
8(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:48:51 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 0.78 One year: 0.97 |
| Support: |
Support1: 0.4 Support2: 0.33 |
| Resistance: |
Resistance1: 0.67 Resistance2: 0.83 |
| Pivot: |
0.54  |
| Moving Average: |
MA(5): 0.59 MA(20): 0.53
MA(100): 0.64 MA(250): 0.85 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 86.9 %D(3): 93 |
| RSI: |
RSI(14): 46.7 |
| 52-week: |
High: 1.63 Low: 0.4 |
| Average Vol(K): |
3-Month: 283 (K) 10-Days: 122 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ UNCY ] has closed below upper band by 42.4%. Bollinger Bands are 21.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.61 - 0.62 |
0.62 - 0.62 |
|
Low:
|
0.53 - 0.54 |
0.54 - 0.54 |
|
Close:
|
0.55 - 0.56 |
0.56 - 0.57 |
|
Company Description |
|
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. |
Headline News |
Thu, 26 Jan 2023
Our Exclusive Articles - Benzinga
Mon, 23 Jan 2023
2023-01-23 | NDAQ:UNCY | Press Release | Unicycive Therapeutics ... - Stockhouse
Thu, 05 Jan 2023
Unicycive Announces Acceptance of Four Abstracts for Presentation ... - Yahoo Finance
Wed, 28 Dec 2022
Is Unicycive Therapeutics Inc (UNCY) Stock a Good Value Wednesday? - InvestorsObserver
Wed, 28 Dec 2022
UNCY stock jumps as kidney disease drug meets main goal in key ... - Seeking Alpha
Mon, 21 Nov 2022
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
15 (M) |
|
% Held by Insiders
|
4.89e+006 (%) |
|
% Held by Institutions
|
41.3 (%) |
|
Shares Short
|
54 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
627.6 |
|
Return on Equity (ttm)
|
-64.6 |
|
Qtrly Rev. Growth
|
951000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-11 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
67370 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
